| Literature DB >> 33466391 |
Evangelia Sereti1,2, Chrisiida Tsimplouli1, Elisavet Kalaitsidou1, Nikos Sakellaridis1, Konstantinos Dimas1.
Abstract
Sigma (σ) receptors have attracted great interest since they are implicated in various cellular functions and biological processes and diseases, including various types of cancer. The receptor family consists of two subtypes: sigma-1 (σ1) and sigma-2 (σ2). Both σ receptor subtypes have been proposed as therapeutic targets for various types of cancers, and many studies have provided evidence that their selective ligands (agonists and antagonists) exhibit antiproliferative and cytotoxic activity. Still, the precise mechanism of action of both σ receptors and their ligands remains unclear and needs to be elucidated. In this study, we aimed to simultaneously determine the expression levels of both σ receptor subtypes in several human cancer cell lines. Additionally, we investigated the in vitro antiproliferative activity of some widely used σ1 and σ2 ligands against those cell lines to study the relationship between σ receptor expression levels and σ ligand activity. Finally, we ran the NCI60 COMPARE algorithm to further elucidate the cytotoxic mechanism of action of the selected σ ligands studied herein.Entities:
Keywords: NCI60 COMPARE analysis; PGRMC1; SIGMAR1; TMEM97; cancer; sigma ligands; sigma receptors
Year: 2021 PMID: 33466391 PMCID: PMC7824900 DOI: 10.3390/biomedicines9010038
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059